Article preview from IN VIVO - October 1, 2011
China Kanghui has emerged as one of the leaders in China's orthopedics industry, building a business first on trauma and, more recently, spine. Now, with a pending move into reconstruction, the company is looking to other emerging markets, and eventually the US and Europe.
Article preview from IN VIVO - October 1, 2011
In emerging markets like China and India, the chronically ill, if frustrated with Western medicine, sometimes find a certain level of relief in so-called traditional treatments that have been used for centuries in Asia. Used by an estimated 80% of the population in some Asian and African countries, according to the World Health Organization, these traditional medicines and treatments might on occasion be a last resort for those suffering from intractable diseases or conditions that simply don't respond to remedies accepted in the West.
One might wonder if medtech investors – particularly those investing in orthopedics – might be open to new alternatives as well. The US market is stagnant. Michael Matson, senior analyst at Mizuho Securities USA Inc., puts his 2012 growth forecast for joint reconstruction and spine to be 1% and 0%, respectively. Even his 6% growth projection for trauma is down a percentage point from last year's growth. "We are reducing our orthopedic market forecasts due to slow economic growth, stubbornly high unemployment, and poor consumer confidence," Matson writes. "We no longer expect a significant rebound in orthopedic procedure growth in 2012."
Continued...
Purchase this article online as a PDF and receive it immediately via email. Questions? Call (800) 332-2181. 100% Satisfaction Guaranteed.
Plus:
To find out about more about more about Elsevier Business Intelligence's medical device publications and databases, multi-user access and/or advertising with Medical Devices Today, please contact Kristy Kennedy at (480) 985-9512
Comments